PMID- 8728047
OWN - NLM
STAT- MEDLINE
DCOM- 19960920
LR  - 20161123
IS  - 0269-9370 (Print)
IS  - 0269-9370 (Linking)
VI  - 10
IP  - 4
DP  - 1996 Apr
TI  - Progression of HIV: follow-up of Edinburgh injecting drug users with narrow 
      seroconversion intervals in 1983-1985.
PG  - 419-30
AB  - OBJECTIVE: To describe progression and survival of individuals infected with HIV 
      by injecting drug use in Edinburgh. DESIGN AND METHODS: From 313 HIV-infected 
      patients with retrospectively estimated narrow seroconversion intervals, 260 
      infected via injecting drug use in the years 1983-1985 were selected for the 
      study group. MAIN OUTCOME MEASURES: The effects of gender, age, human leukocyte 
      antigen (HLA) type and zidovudine (ZDV) treatment on progression and survival 
      from seroconversion; Weibull estimates of the AIDS incubation distribution and 
      the overall survival distribution; slopes of absolute CD4 lymphocyte loss (on the 
      square root scale) and loss of CD4 percentage. RESULTS: The cumulative 
      progression rates at 10 years were 68% to CDC stage IV and 31% to AIDS with a 
      mortality rate of 25%. Three-year survival rates for AIDS and CDC stage IV cases 
      were 25 and 72%, respectively. Gender and age effects on progression or overall 
      survival were not found, although those aged over 30 years experienced poorer 
      survival from AIDS. A strong HLA (A1, B8, DR3) association with faster 
      progression and poorer survival was found. Median survival was estimated by 
      Weibull distribution to be 12.6 years; median AIDS-free time was estimated to be 
      11.6 years. CD4 cell loss was approximately linear when transformed to the square 
      root scale as was the decline in CD4 percentage. Only HLA effects on slopes were 
      found: A1,B8, DR3 was significantly associated with faster loss of both absolute 
      CD4 cells and CD4 percentage (P < 0.001) and B27 was significantly associated 
      with slower loss of CD4 percentage (P = 0.01). CONCLUSIONS: Edinburgh IDU do not 
      seem to progress more rapidly than other cohorts with predominantly different 
      risk activities. Older age was associated with poorer survival from AIDS but no 
      gender effect was found for progression or overall survival. The clearest 
      significant association with AIDS progression, mortality and loss of CD4 cells 
      was the phenotype HLA A1,B8,DR3. In contrast HLA B27 was associated with slower 
      loss of CD4 cells.
FAU - Brettle, R P
AU  - Brettle RP
AD  - Regional Infectious Disease Unit, City Hospital, Edinburgh, UK.
FAU - McNeil, A J
AU  - McNeil AJ
FAU - Burns, S
AU  - Burns S
FAU - Gore, S M
AU  - Gore SM
FAU - Bird, A G
AU  - Bird AG
FAU - Yap, P L
AU  - Yap PL
FAU - MacCallum, L
AU  - MacCallum L
FAU - Leen, C S
AU  - Leen CS
FAU - Richardson, A M
AU  - Richardson AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - AIDS
JT  - AIDS (London, England)
JID - 8710219
RN  - 0 (Antiviral Agents)
RN  - 4B9XT59T7S (Zidovudine)
SB  - IM
MH  - Adult
MH  - Age Factors
MH  - Antiviral Agents/therapeutic use
MH  - CD4 Lymphocyte Count
MH  - Disease Progression
MH  - Follow-Up Studies
MH  - HIV Infections/drug therapy/*epidemiology/immunology/mortality
MH  - HIV Seropositivity/*epidemiology/immunology
MH  - Histocompatibility Testing
MH  - Humans
MH  - Male
MH  - Statistics as Topic
MH  - *Substance Abuse, Intravenous
MH  - United Kingdom/epidemiology
MH  - Zidovudine/therapeutic use
EDAT- 1996/04/01 00:00
MHDA- 1996/04/01 00:01
CRDT- 1996/04/01 00:00
PHST- 1996/04/01 00:00 [pubmed]
PHST- 1996/04/01 00:01 [medline]
PHST- 1996/04/01 00:00 [entrez]
PST - ppublish
SO  - AIDS. 1996 Apr;10(4):419-30.